Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

Summary

This pilot, phase I trial studies the side effects and best dose of bortezomib in treating patients with acquired immune deficiency syndrome (AIDS)-related Kaposi sarcoma that has come back or has not responded to treatment. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2010-01-22

Primary completion

2015-01-07

Completion

2015-01-07

Drugs

Indications